Research criteria for defining patients with CIDP

Neurology

Volumn 60, Issue 8 SUPPL. 3, 2003, Pages

  Sander, Howard W ^a,b   Latov, Norman ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB;

CEREBROSPINAL FLUID EXAMINATION; CHRONIC DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DEMYELINATING NEUROPATHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ELECTRODIAGNOSIS; ELECTROPHYSIOLOGY; HUMAN; LABORATORY TEST; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR NEUROPATHY; NERVE BIOPSY; NERVE BLOCK; NEUROLOGIC EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; SENSORY NEUROPATHY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037461303     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.60.8_suppl_3.s8     Document Type: Conference Paper

References (49)

1. McCleod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910-913.
2. Mygland A, Monstadt P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001;8:157-165.
3. Cornblath DR, Feasby TE, Hahn AF, et al. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-618.
4. Brannagan TH III, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002;58:1856-1858.
5. Bromberg MB. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991;14:968 -976.
6. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
7. Magda P, Latov N, Brannagan TH, Chin RL, Sander HW. Minimal electrodiagnostic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 2003;60:A489.
8. Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999;22:560-566.
9. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
10. Nicolas G, Maisonobe T, Le Forestier N, Léger J-M, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2002;25:26-30.
11. Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002;59:1526-1532.
12. Barohn RJ, Saperstein DS. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Semin Neurol 1998;18:49-61.
13. Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-637.
14. Bouchard C, Lacroix C, Planté V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999;52:498-503.
15. Trojaborg W. Acute and chronic neuropathies: new aspects of Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, an overview and an update. Electroencephalogr Clin Neurophysiol 1998;107:303-316.
16. Nagamatsu M, Terao S, Misu K, et al. Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1999;66:727-733.
17. Rotta FT, Sussman AT, Bradley WG, Ayyar DR, Sharma KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173:129-139.
18. Oh SJ, Melo AC, Lee DK, et al. Large-fiber neuropathy in distal sensory neuropathy with normal routine nerve conduction. Neurology 2001;56:1570-1572.
19. Wilson JR, Park Y, Fisher MA. Electrodiagnostic criteria in CIDP: comparison with diabetic neuropathy. Electromyogr Clin Neurophysiol 2000;40:181-185.
20. Haq RU, Fries TJ, Pendlebury WW, Kenny MJ, Badger GJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria. Arch Neurol 2000;57:1745-1750.
21. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-324.
22. Bosboom WMJ, van den Berg LH, Franssen H, et al. Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy. Brain 2001;124:2427-2438.
23. Chin RL, Latov N, Hays AP, Croul SE, Magda P, Sander HW, Brannagan TH. Chronic inflammatory demyelinating polyneuropathy (CIDP) presenting as cryptogenic sensory polyneuropathy. Neurology 2003;60: A314.
24. Sander HW, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises: Case 6-2003. A nine-year-old girl with progressive weakness and areflexia. N Engl J Med 2003;348:735-743.
25. American Association of Electrodiagnostic Medicine, American Academy of Neurology. American Academy of Physical Medicine and Rehabilitation. Recommended Policy for Electrodiagnostic Medicine. Available at: http://www.aaem.net/aaem/practiceissues/RecPolicy/ recommended_policy_1.cfm. Accessed January 17, 2003.
26. Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000;23:37-43.
27. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54:615-620.
28. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328.
29. Miescher GC, Latov N, Steck AJ. Dysglobulinemic neuropathies. In: Antel J, Birnbaum G, Hartung H-P, eds. Clinical immunology. London: Blackwell Science, 1998:307-315.
30. Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropathy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992;55:677-680.
31. Van Dijk GW, Notermans NC, Franssen H, Wokke JH. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long term follow-up study. J Neurol 1999;246:1134-1139.
32. Ohkoshi N, Harada K, Nagata H, Yato M, Shoji S. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy: clinical features and pathological study of sural nerves. Eur Neurol 2001;45:241-248.
33. Krarup C, Trojaborg W. Sensory pathophysiology in chronic acquired demyelinating neuropathy. Brain 1996;19:257-270.
34. Katz JS, Wolfe GI, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Electrophysiologic findings in multifocal motor neuropathy. Neurology 1997;48:700-707.
35. Krarup C, Stewart JD, Sumner AJ, Pestronk A, Lipton SA. A syndrome of asymmetric limb weakness with motor conduction block. Neurology 1990;40:118-127.
36. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001;115:4-18.
37. Kinsella LJ, Lange DJ, Trojaborg W, Sadiq SA, Younger DS, Latov N. Clinical and electrophysiologic correlates of elevated anti-GM1 antibody titers. Neurology 1994;44:1278-1282.
38. Oh SJ, Claussen GC, Kim DS. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy? J Peripher Nerv Syst 1997;2:362-369.
39. Azulay JP, Blin O, Pouget J, et al. Intravenous gammaglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double blind, placebo-controlled study. Neurology 1994;44:429-432.
40. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous gammaglobulin: a double blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1995;59:28-52.
41. Federico P, Zochodne DW, Hahn A, et al. Multifocal motor neuropathy improved by IVIg: randomized double-blind, placebo controlled study. Neurology 2000;55:1256-1262.
42. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982;32:958-964.
43. Amato AA, Jackson CE, Kim JY, Worley KL. Chronic relapsing brachial plexus neuropathy with persistent conduction block. Muscle Nerve 1997;20:1303-1307.
44. Gorson KC, Ropper AH, Weinberg DH. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 1999;22:758-765.
45. Van den Berg-Vos RM, Van den Berg LH, Franssen H, et al. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology 2000;54:26-32.
46. Alaedini A, Sander HW, Hays AP, Latov N. Anti-ganglioside antibodies in multifocal acquired sensory and motor neuropathy. Arch Neurol 2003;60:42-46.
47. Latov N. Prognosis of neuropathy and monoclonal gammopathy. Muscle Nerve 2000;23:150-152.
48. Comi G, Roveri L, Swan A, et al. A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002;249:1370-1377.
49. Renaud S, Gregor M, Fuhr P, et al. Rituximab and anti-MAG associated polyneuropathy: a pilot study. Neurology 2001;56(suppl 3):A396. Abstract.